Antipodean

Antipodean Pharmaceuticals is a clinical-stage biotechnology company specializing in the development of mitochondrial-targeted antioxidants. The company's core technology involves the use of a lipophilic cation to deliver antioxidant compounds, such as ubiquinone, directly into the mitochondria to combat oxidative stress. Its lead candidate, MitoQ (mitoquinone mesylate), was evaluated in Phase 2 clinical trials for the treatment of liver damage associated with Hepatitis C and for slowing the progression of Parkinson's disease. Although the pharmaceutical development of MitoQ has largely transitioned to the nutraceutical market under the entity MitoQ Limited, the original company laid the groundwork for mitochondrial-targeted therapies. The company's approach aimed to address the root cause of many degenerative diseases by protecting mitochondrial function.